Concentra, a company in occupational medicine in the US, has opened a new medical centre in Katy, Texas. The facility, named Concentra Katy, is situated at 25805 Katy Freeway, Suite 600, and is set to ...

Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity ...

Concentra®, the nation’s leader in occupational medicine, today announced the opening of a new medical center in Katy, Texas.

Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a ...

In a report released today, Ben Hendrix from RBC Capital reiterated a Buy rating on Concentra Group Holdings Parent, Inc. (CON – Research ...

JPMorgan analyst Lisa Gill raised the firm’s price target on Concentra (CON) to $30 from $29 and keeps an Overweight rating on the shares.

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.

Acelyrin (NASDAQ:SLRN) stock in focus as the company adopts a poison pill to counter rapid stock acquisition by Tang Capital Partners. Read more here.